Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 117
Filter
2.
J Periodontal Res ; 53(1): 117-122, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29139559

ABSTRACT

BACKGROUND AND OBJECTIVE: It is well known that there is a strong relationship between periodontitis and cardiovascular disease (CVD). Tooth loss reflects an end-stage condition of oral diseases, such as periodontitis. Infection with specific periodontal pathogens is known as a possible factor that influences development of CVD. The aim of this study was to assess the relationship between the number of residual teeth and systemic inflammatory conditions in patients with CVD. MATERIAL AND METHODS: We divided 364 patients with CVD into four groups, according to the number of residual teeth: (i) ≥20 teeth; (ii) 10-19 teeth; (iii) 1-9 teeth; and (iv) edentulous. We recorded medical history, blood data and periodontal conditions. Serum samples were obtained and their IgG titers against three major periodontal pathogens were measured. RESULTS: Smoking rate and the prevalence of diabetes mellitus were higher in edentulous patients and in subjects with a few teeth compared with patients with many teeth. The levels of C-reactive protein were higher in patients with 1-9 teeth than in those with 10-19 teeth and with ≥20 teeth. The level of Porphyromonas gingivalis IgG in the group with 10-19 teeth was statistically higher than that in the group with ≥20 teeth. The level of P. gingivalis IgG in the edentulous group tended to be lower than that in the other groups. CONCLUSION: The patients with 1-9 teeth had the highest level of C-reactive protein among the four groups, and the patients with 10-19 teeth had the highest level of IgG to periodontal bacteria. We conclude that the number of remaining teeth may be used to estimate the severity of systemic inflammation in patients with CVD.


Subject(s)
Antibodies, Bacterial/blood , C-Reactive Protein/analysis , Cardiovascular Diseases/complications , Porphyromonas gingivalis/immunology , Tooth Loss/complications , Aged , Aged, 80 and over , Cardiovascular Diseases/blood , Female , Humans , Immunoglobulin G/blood , Japan , Jaw, Edentulous , Jaw, Edentulous, Partially , Male
3.
J Periodontal Res ; 47(4): 463-9, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22181324

ABSTRACT

BACKGROUND AND OBJECTIVE: Although clarithromycin (CAM) has many biological functions, including regulation of MMPs, little is known about its effect on abdominal aortic aneurysms. Periodontopathic bacteria have been reported to be associated with several kinds of circulatory diseases. The purpose of this study was therefore to clarify the effect of CAM on periodontopathic bacteria-accelerated abdominal aortic aneurysms. MATERIAL AND METHODS: Abdominal aortic aneurysm was produced in mice by the peri-aortic application of 0.25 m CaCl(2). The mice were inoculated once per week with live Porphyromonas gingivalis, which is one of the major periodontopathic bacteria. Test mice (n=8) were given a daily oral dose of CAM, while control mice (n=13) were not. RESULTS: Four weeks after the operation, the P. gingivalis-injected and CAM-treated mice showed a significant decrease in the aortic diameter in comparison with the mice only injected with P. gingivalis. Histopathologically, the samples obtained from the P. gingivalis-injected and CAM-treated mice showed less elastic degradation. Moreover, the plasma MMP-2 concentration of the CAM-treated mice decreased significantly. CONCLUSION: These findings suggest that CAM administration is useful to suppress periodontal bacteria-accelerated abdominal aortic aneurysms via MMP regulation.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Aortic Aneurysm, Abdominal/drug therapy , Aortic Aneurysm, Abdominal/microbiology , Clarithromycin/therapeutic use , Matrix Metalloproteinase Inhibitors/therapeutic use , Protein Synthesis Inhibitors/therapeutic use , Animals , Anti-Bacterial Agents/pharmacology , Aortic Aneurysm, Abdominal/pathology , Clarithromycin/pharmacology , Doxycycline/pharmacology , Doxycycline/therapeutic use , Male , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 9/blood , Matrix Metalloproteinase Inhibitors/blood , Mice , Mice, Inbred C57BL , Porphyromonas gingivalis , Protein Synthesis Inhibitors/pharmacology , Tissue Inhibitor of Metalloproteinase-1/blood
4.
J Periodontal Res ; 46(2): 176-83, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21143481

ABSTRACT

BACKGROUND AND OBJECTIVE: Abdominal aortic aneurysm (AAA) is a common and lethal disorder, and MMPs are highly expressed in AAA lesions. Large numbers of periodontopathic bacteria have been reported to be present in specimens obtained from the aortic walls of patients with an AAA. The purpose of this study was to analyze the influence of periodontopathic bacteria on AAA dilatation. MATERIAL AND METHODS: AAAs were produced in mice by the periaortic application of 0.25 M CaCl(2), and NaCl was used as a control. The mice were inoculated once weekly with live Porphyromonas gingivalis, live Aggregatibacter actinomycetemcomitans or vehicle. RESULTS: Four weeks after the periaortic application of either CaCl(2) or NaCl, a significant increase was observed in the aortic diameter of P. gingivalis-challenged mice compared with the vehicle control mice (p < 0.05), whereas there was no statistically significant increase in the aortic diameter of the A. actinomycetemcomitans-challenged mice. Immunohistochemical analysis found significantly higher numbers of CD8-positive and MOMA2-positive cells and significantly higher levels of MMP-2 in the aneurysmal samples of P. gingivalis-challenged mice compared with control mice. Live P. gingivalis promoted a significant proliferation of splenocytes in comparison with P. gingivalis-lipopolysaccharide and live A. actinomycetemcomitans (p < 0.05). CONCLUSION: These findings demonstrate that challenge with P. gingivalis, but not with A. actinomycetemcomitans, can accelerate, or even initiate, the progression of experimental AAA through the increased expression of MMPs.


Subject(s)
Aortic Aneurysm, Abdominal/microbiology , Bacteroidaceae Infections/enzymology , Matrix Metalloproteinase 2/biosynthesis , Porphyromonas gingivalis/enzymology , Actinobacillus Infections/enzymology , Aggregatibacter actinomycetemcomitans/enzymology , Aggregatibacter actinomycetemcomitans/immunology , Animals , Antibodies, Bacterial/blood , Aorta, Abdominal/drug effects , Aorta, Abdominal/microbiology , Aortic Aneurysm, Abdominal/enzymology , Aortitis/chemically induced , Aortitis/microbiology , CD8-Positive T-Lymphocytes/pathology , Calcium Chloride/adverse effects , Cell Proliferation/drug effects , Disease Models, Animal , Disease Progression , Enzyme Induction , Immunoglobulin G/blood , Lipopolysaccharides/pharmacology , Male , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 9/blood , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Porphyromonas gingivalis/immunology , Spleen/drug effects , Spleen/enzymology , Spleen/pathology , Tissue Inhibitor of Metalloproteinase-1/blood
5.
Aliment Pharmacol Ther ; 25(9): 1105-13, 2007 May 01.
Article in English | MEDLINE | ID: mdl-17439512

ABSTRACT

BACKGROUND: Large-scale studies of rabeprazole-based Helicobacter pylori eradication therapy have not been reported in Japan. AIMS: To evaluate H. pylori eradication by rabeprazole-based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages. METHODS: From 35 centres 479 H. pylori-positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days); Group 2 (10 mg, 750 mg, 400 mg); Group 3 (20 mg, 750 mg, 200 mg) and Group 4 (20 mg, 750 mg, 400 mg). RESULTS: Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1-4, respectively. The eradication rate was 95% (360 of 379) for clarithromycin-susceptible strains, and 50% (30 of 60) for clarithromycin-resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively. CONCLUSIONS: Rabeprazole-based therapies achieved 50% eradication of clarithromycin-resistant H. pylori, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first-line proton pump inhibitor-based triple therapy for H. pylori.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Helicobacter Infections/prevention & control , Helicobacter pylori , Peptic Ulcer/drug therapy , Amoxicillin/therapeutic use , Clarithromycin/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Peptic Ulcer/microbiology , Rabeprazole , Treatment Outcome
6.
Dig Liver Dis ; 39(2): 130-5, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17161670

ABSTRACT

BACKGROUND: Even with the most effective treatment, Helicobacter pylori eradication is difficult in some patients. Therefore, patients sometimes require acid-suppressive therapy without H. pylori eradication. It has been reported that ranitidine inhibits neutrophil activation, whereas famotidine does not. However, few studies have been published concerning the activation of neutrophils before and after treatment using clinical doses of histamine-2 receptor antagonists in patients with H. pylori infection. AIM: To examine the effects of neutrophil activation after treatment with three different histamine-2 receptor antagonists. PATIENTS: This prospective, open-label, randomised, parallel-group study was conducted. Thirty patients with H. pylori infection were enrolled. These subjects were randomly assigned to receive one of the following treatments: (a) 150 mg ranitidine, (b) 20mg famotidine, or (c) 10 mg lafutidine b.d., for 4 weeks. Before and after histamine-2 receptor antagonist treatment, histological findings, myeloperoxidase activity, and interleukin-8 in the gastric mucosa were evaluated. RESULTS: On the basis of the histological findings between before and after histamine-2 receptor antagonist treatment, no significant differences were found in any groups. Similarly, there were no significant differences in myeloperoxidase activity or interleukin-8 levels. CONCLUSION: In patients with H. pylori, when used at clinical doses, any histamine-2 receptor antagonists can be used without concerning about inhibition of neutrophil activation.


Subject(s)
Dyspepsia/drug therapy , Helicobacter Infections/complications , Helicobacter pylori , Histamine H2 Antagonists/pharmacology , Histamine H2 Antagonists/therapeutic use , Neutrophil Activation/drug effects , Acetamides/therapeutic use , Adult , Dyspepsia/etiology , Famotidine/therapeutic use , Female , Helicobacter pylori/drug effects , Humans , Interleukin-8/metabolism , Male , Middle Aged , Peroxidase/metabolism , Piperidines/therapeutic use , Pyridines/therapeutic use , Ranitidine/therapeutic use
7.
Br J Cancer ; 96(1): 89-94, 2007 Jan 15.
Article in English | MEDLINE | ID: mdl-17179982

ABSTRACT

The technique of endoscopic submucosal dissection (ESD) has been developed for en bloc resection of early gastric cancer (EGC); however, little is known about the risk of metachronous cancer in the remnant stomach after initial ESD. In this study, we investigated the correlation between microsatellite instability (MSI) status and the incidence of metachronous recurrence of gastric cancer. According to the genetic/molecular background determined with MSI status and expression levels of hMLH1 and p53 tumour suppressor, 110 EGCs removed with ESD were subclassified into three groups: the mutator/MSI-type (8%), suppressor/p53-type (45%) and unclassified type (47%). Interestingly, patients with the mutator/MSI-type tumour had a high incidence (67%) of metachronous recurrence of gastric cancer within a 3-year observation after initial ESD, which was significantly higher than those with the suppressor/p53-type and unclassified type tumours (P<0.01). Although we investigated mucin phenotypes, there was no correlation between mucin phenotype and the recurrence of EGC. These findings suggest that subclassification of molecular pathological pathways in EGCs is required for the assessment of patients with a high risk of recurrent gastric cancer. The information delivered from our investigation is expected to be of value for decisions about therapy and surveillance after ESD.


Subject(s)
Endoscopy, Gastrointestinal , Microsatellite Instability , Neoplasm Recurrence, Local/genetics , Stomach Neoplasms/genetics , Stomach Neoplasms/surgery , Aged , Biomarkers, Tumor/genetics , Endoscopy, Gastrointestinal/methods , Epithelial Cells/metabolism , Female , Follow-Up Studies , Humans , Immunohistochemistry , Male , Mucins/genetics , Phenotype , Predictive Value of Tests , Sensitivity and Specificity , Stomach Neoplasms/pathology , Tumor Suppressor Protein p53/genetics
8.
Genes Brain Behav ; 5(4): 364-8, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16716206

ABSTRACT

Several lines of evidence suggest that metabolic changes in the kynurenic acid (KYNA) pathway are related to the etiology of schizophrenia. The inhibitor of kynurenine 3-monooxygenase (KMO) is known to increase KYNA levels, and the KMO gene is located in the chromosome region associated with schizophrenia, 1q42-q44. Single-marker and haplotype analyses for 6-tag single nucleotide polymorphisms (SNPs) of KMO were performed (cases = 465, controls = 440). Significant association of rs2275163 with schizophrenia was observed by single-marker comparisons (P = 0.032) and haplotype analysis including this SNP (P = 0.0049). Significant association of rs2275163 and haplotype was not replicated using a second, independent set of samples (cases = 480, controls = 448) (P = 0.706 and P = 0.689, respectively). These results suggest that the KMO is unlikely to be related to the development of schizophrenia in Japanese.


Subject(s)
Chromosomes, Human, Pair 1/genetics , Genetic Predisposition to Disease , Kynurenine 3-Monooxygenase/genetics , Schizophrenia/genetics , Aged , Case-Control Studies , Chi-Square Distribution , Epigenesis, Genetic , Female , Gene Frequency , Humans , Japan , Kynurenic Acid/metabolism , Kynurenine 3-Monooxygenase/metabolism , Linkage Disequilibrium , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics
9.
Dig Liver Dis ; 37(11): 821-5, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16040284

ABSTRACT

BACKGROUND: The ideal second-line treatment regimens for Helicobacter pylori infection may differ between the areas, countries and races. AIM: The aim was to confirm which was the better regimen for second-line therapy after treatment failure with a standard triple therapy in Japan, a high dosage of levofloxacin- or metronidazole-based therapy. PATIENTS: Sixty outpatients with persistent H. pylori infection after a standard triple therapy were enrolled in this prospective, open-label and randomised trial. METHODS: The subjects were randomly administered levofloxacin (300 mg b.d.)- or metronidazole (500 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days, and the cure rates and side effects were analysed. Antimicrobial susceptibility was also examined before second-line therapy using the E-test. RESULTS: Good compliance was obtained without severe side effects in both the groups except for two patients. The cure rates, expressed as intention-to-treat and per-protocol analyses, respectively, were 70.0 and 72.4% in the levofloxacin group, and 96.7 and 100% in the metronidazole group. Each regimen often overcame even clarithromycin-resistant strains. CONCLUSION: Metronidazole-based triple therapy is recommended as second-line therapy in Japan, and levofloxacin-based therapy can be an alternative treatment option.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Helicobacter Infections/drug therapy , Levofloxacin , Metronidazole/therapeutic use , Ofloxacin/therapeutic use , Adult , Aged , Drug Therapy, Combination , Female , Helicobacter pylori , Humans , Japan , Male , Middle Aged , Prospective Studies
10.
Ann Bot ; 96(3): 467-77, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15994841

ABSTRACT

BACKGROUNDS AND AIMS: Echinacea angustifolia is a widespread species distributed throughout the Great Plains region of North America. Genetic differentiation among populations was investigated along a 1500 km north-south climatic gradient in North America, a region with no major geographical barriers. The objective of the study was to determine if genetic differentiation of populations could be explained by an isolation-by-distance model or by associations with climatic parameters known to affect plant growth and survival. METHODS: Historical climatic data were used to define the nature of the climatic gradient and AFLP markers were used to establish patterns of population genetic differentiation among ten Echinacea populations collected from North Dakota to Oklahoma. A total of 1290 fragments were scored using six EcoRI/MseI and three PstI/MseI primer combinations. Assessment of the correlation between climatic, genetic and geographic distances was assessed by Mantel and partial Mantel tests. KEY RESULTS: PstI/MseI combinations produced significantly fewer fragments, but a larger percentage was unique compared with EcoRI/MseI markers. Using estimates of F(ST), populations in Oklahoma and southern Kansas were identified as the most divergent from the other populations. Both the neighbour-joining tree and principal co-ordinate analysis clustered the populations in a north-south spatial orientation. About 60% of the genetic variation was found within populations, 20% among populations and the remaining 20% was partitioned among groups that were defined by the topology of the neighbour-joining tree. Significant support was found for the isolation-by-distance model independent of the effects of annual mean precipitation, but not from annual mean temperature and freeze-free days. CONCLUSIONS: Echinacea angustifolia populations exhibit genetic divergence along a north-south climatic gradient. The data support an isolation-by-distance restriction in gene flow that is independent of annual mean precipitation.


Subject(s)
Climate , Echinacea/genetics , Genetic Variation , Adaptation, Physiological/genetics , DNA, Plant/analysis , DNA, Plant/genetics , Demography , Genes, Plant , Phylogeny
11.
Aliment Pharmacol Ther ; 21(11): 1331-9, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15932363

ABSTRACT

BACKGROUND: The polymorphic enzyme cytochrome P450 2C19 affects omeprazole metabolism. This influence on metabolism might affect serum gastrin levels, and safety, during long-term treatment of reflux oesophagitis. AIM: To examine the relationship between cytochrome P450 2C19 genotype and the safety profile of long-term omeprazole treatment. METHODS: A total of 119 Japanese patients with recurrent reflux oesophagitis underwent cytochrome P450 2C19 genotyping prior to receiving daily omeprazole 10 mg or 20 mg for 6-12 months, during which adverse event frequency, serum gastrin levels and endoscopic findings were monitored. RESULTS: The incidences of adverse events, serious adverse events and adverse events leading to withdrawal did not differ between homozygous extensive metabolizer (n = 46), heterozygous extensive metabolizer (n = 53) or poor metabolizer (n = 20) groups. In all genotype groups, serum gastrin increased during the first 3 months of dosing but stabilized thereafter. No significant differences were seen either in the rate of reflux oesophagitis healing or symptom improvement among genotype groups. CONCLUSIONS: Long-term treatment with omeprazole was well-tolerated in Japanese patients, irrespective of their cytochrome P450 2C19 metabolic genotype, indicating that dose adjustment depending on metabolic genotype is not required during treatment with omeprazole.


Subject(s)
Anti-Ulcer Agents/administration & dosage , Aryl Hydrocarbon Hydroxylases/genetics , Esophagitis, Peptic/genetics , Gastroesophageal Reflux/genetics , Mixed Function Oxygenases/genetics , Omeprazole/administration & dosage , Polymorphism, Genetic/genetics , Adult , Aged , Anti-Ulcer Agents/adverse effects , Anti-Ulcer Agents/metabolism , Cytochrome P-450 CYP2C19 , Esophagitis, Peptic/drug therapy , Esophagitis, Peptic/metabolism , Female , Gastrins/blood , Gastroesophageal Reflux/drug therapy , Gastroesophageal Reflux/metabolism , Genotype , Heterozygote , Homozygote , Humans , Male , Middle Aged , Omeprazole/adverse effects , Omeprazole/metabolism , Recurrence , Treatment Outcome
15.
Dig Liver Dis ; 36(3): 178-86, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15046186

ABSTRACT

BACKGROUND: Proliferation and apoptosis events are altered in Helicobacter pylori infection. However, whether H. pylori eradication has an effect on the disturbed kinetics in metaplastic mucosa has not been well elucidated. AIM: To investigate the effect of eradication on the gastric cell kinetics. SUBJECTS AND METHODS: Initially, biopsies were obtained from 74 H. pylori-infected subjects and repeated 12 and 24 months after eradication. Biopsies were immunohistochemically stained for apoptosis by single-stranded DNA, for proliferation by Ki-67 antibodies and for intestinal metaplasia MUC2, MUC5AC, MUC6 and CD10. RESULTS: While antral apoptosis in intestinal metaplasia was significantly lower than in non-intestinal metaplasia, proliferation was significantly higher (greater and lesser curvatures, P < 0.05, respectively). This resulted in a significantly lower apoptosis/proliferation ratio in intestinal metaplasia than in non-intestinal metaplasia (antrum greater and lesser curvatures and corpus greater curvature, P < 0.05). After successful eradication, apoptosis and proliferation decreased in both intestinal metaplasia and non-intestinal metaplasia. The pattern of reduction of apoptosis and proliferation differed in these two groups. However, in the corpus, the reduction resulted in a significant increase in the apoptosis/proliferation ratio in both. CONCLUSION: Proliferation and apoptosis are unevenly and disproportionately altered in H. pylori infection leading to an imbalance in cell kinetics. Eradication of the organism improves the balance and may possibly play a role in the prevention of malignancy transformation in the metaplastic mucosa.


Subject(s)
Gastric Mucosa/pathology , Helicobacter Infections/pathology , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Apoptosis/drug effects , Apoptosis/genetics , Cell Division/drug effects , Endoscopes, Gastrointestinal , Female , Follow-Up Studies , Gastric Mucosa/chemistry , Gastric Mucosa/drug effects , Helicobacter Infections/drug therapy , Helicobacter Infections/metabolism , Helicobacter pylori/drug effects , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Kinetics , Male , Metaplasia , Middle Aged
16.
Dig Liver Dis ; 35(10): 711-5, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14620620

ABSTRACT

BACKGROUND: Successful eradication of Helicobacter pylori infection after failure of standard triple therapy is difficult. The efficacy and safety of levofloxacin based triple therapy as a first-line therapy has-been studied. AIMS: The aim was to evaluate the efficacy and tolerability of levofloxacin based therapy after a failed standard triple therapy. PATIENTS: We conducted a prospective, uncontrolled study of a consecutive series of 33 patients who failed eradication with 1 week of lansoprazole-amoxicillin-clarithromycin triple therapy. METHODS: The subjects were retreated with 1 week of LA-LVFX triple therapy (lansoprazole, 30 mg twice daily; amoxicillin, 1000 mg twice daily: levofloxacin, 200 mg twice daily). Cure of infection was defined as negative results from culture, histology and a urea breath test 4 to 8 weeks after the second-line therapy. RESULTS: The eradication rate was 69.7% (23/33) by both intention-to-treat and per-protocol analyses (95% confidence interval=61-79%). Seven (21.2%) patients experienced mild side-effects, such as soft stools and taste disturbance. No patient stopped the medication on account of adverse effects. CONCLUSIONS: Levofloxacin based triple therapy is an effective second-line treatment after a failed standard triple therapy.


Subject(s)
Anti-Infective Agents/therapeutic use , Helicobacter Infections/drug therapy , Helicobacter pylori , Levofloxacin , Ofloxacin/therapeutic use , Omeprazole/analogs & derivatives , 2-Pyridinylmethylsulfinylbenzimidazoles , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Clarithromycin/therapeutic use , Drug Therapy, Combination , Female , Helicobacter pylori/drug effects , Humans , Lansoprazole , Male , Microbial Sensitivity Tests , Middle Aged , Omeprazole/therapeutic use , Prospective Studies , Proton Pump Inhibitors , Treatment Failure
17.
J Exp Clin Cancer Res ; 22(1): 117-23, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12725331

ABSTRACT

Carcinoma cells with high metastatic potential often show a dedifferentiated phenotype at the primary site. In this study, a total of 48 cases (24 primary tumors of colorectal cancer (Pr-CRC) with liver metastasis, 24 without) were examined for E-cadherin and ZO-1 expression by immunohistochemical staining, and for their dedifferentiated phenotype. The expression levels of E-cadherin and ZO-1 were markedly decreased in the cancer cells of tumors with liver metastasis. Moreover, dedifferentiation of cancer cells, which was evaluated by the modified Gleason score, was also related to liver metastasis. However, none of the conventional clinicopathologic parameters of invasion, except lymph node metastasis, showed any relationship with liver metastasis. These results indicate that dedifferentiation and a decreased expression of E-cadherin and ZO-1 are closely related to liver metastasis.


Subject(s)
Cadherins/metabolism , Cell Adhesion Molecules/metabolism , Colonic Neoplasms/pathology , Colorectal Neoplasms/pathology , Gene Expression Regulation, Neoplastic , Liver Neoplasms/secondary , Membrane Proteins/metabolism , Phosphoproteins/metabolism , Rectal Neoplasms/pathology , Cell Differentiation , Chi-Square Distribution , Female , Humans , Immunohistochemistry , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Metastasis , Zonula Occludens-1 Protein
19.
Eur J Cancer ; 38(14): 1879-87, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12204670

ABSTRACT

Metallothionein (MT) expression is observed in various carcinomas, but its role is not fully understood. To clarify the clinicopathological significance of MT, 87 colorectal adenomas and 128 early-stage carcinomas were immunohistochemically analysed for MT expression. The degree of MT immunostaining of a specimen was graded according to the proportion of MT-positive cells; negative (<5%) and positive (focally 5-50%, diffusely >50%). MT expression significantly decreased with tumour development. For carcinomas, MT-positivity was significantly associated with depth of invasion (T1 60% versus T2 33%; P<0.01), vascular involvement (positive 35% versus negative 61%; P<0.01) and morphology (polypoid 62% versus depressed 26%; P<0.01). Regarding MT-positive distribution, the diffuse-positive rate in MT-positive polypoid lesions was 28%, while MT-positive depressed lesions were all diffusely stained (P<0.01). In conclusion, our results suggested that decreasing MT expression is an early event in colorectal carcinogenesis and may reflect local invasion. Furthermore, MT-positive distribution may reflect genetic differences between the polypoid and depressed-type.


Subject(s)
Colorectal Neoplasms/metabolism , Metallothionein/metabolism , Neoplasm Proteins/metabolism , Adult , Aged , Aged, 80 and over , Colonic Polyps/metabolism , Female , Humans , Immunohistochemistry/methods , Intestinal Mucosa/metabolism , Male , Middle Aged , Proliferating Cell Nuclear Antigen/metabolism
20.
Acta Neurochir Suppl ; 81: 281-3, 2002.
Article in English | MEDLINE | ID: mdl-12168326

ABSTRACT

OBJECTIVE: Cerebral contusion is sometimes associated with a non-hemorrhagic mass effect which progresses rapidly within 12-48 hours post-trauma. In order to determine the mechanisms underlying such a mass effect, we analyzed data obtained from ICP monitoring and diffusion MRI in a total of 38 patients with cerebral contusion. METHODS: Diffusion imaging and ADC mapping were performed employing 1.5 T echo planar MRI. ADC values were expressed as a ratio relative to the values of intact brain areas. RESULTS: In 6 patients, ICP became uncontrollable medically and surgical resection of the contused brain tissue was eventually performed. Within 24 hours post-trauma, diffusion images revealed a low intensity core and a high intensity rim in the contusion. The ADC ratio increased in the central area (1.13 +/- 0.21) and decreased in the peripheral area (0.67 +/- 0.14). A crescent-shaped zone of very high ADC ratio (1.45 +/- 0.14) was observed at the border between these two areas during the period of 24-48 hours. CONCLUSIONS: It appears that the capacitance of edema fluid accumulation is elevated by cellular disintegration in the central area, whereas the resistance to edema fluid propagation is elevated by cellular swelling in the peripheral area. We suggest that such events facilitate extracellular edema fluid accumulation within contused brain tissue and contribute, together with cellular swelling itself, to the non-hemorrhagic mass effect of cerebral contusion.


Subject(s)
Brain Concussion/diagnosis , Brain Concussion/physiopathology , Intracranial Pressure , Monitoring, Physiologic/methods , Brain Concussion/pathology , Brain Mapping , Humans , Magnetic Resonance Imaging , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...